These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35944511)

  • 1. Evaluating the Effectiveness of a Telehealth Cancer Genetics Program: A BRCA Pilot Study.
    Rose E; Hardy MW; Gates R; Stanislaw C; Meisel J; Grinzaid KA
    Public Health Genomics; 2022 Aug; ():1-14. PubMed ID: 35944511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: a cohort study.
    Manchanda R; Burnell M; Gaba F; Sanderson S; Loggenberg K; Gessler S; Wardle J; Side L; Desai R; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    BJOG; 2019 May; 126(6):784-794. PubMed ID: 30767407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
    Manchanda R; Burnell M; Gaba F; Desai R; Wardle J; Gessler S; Side L; Sanderson S; Loggenberg K; Brady AF; Dorkins H; Wallis Y; Chapman C; Jacobs C; Legood R; Beller U; Tomlinson I; Menon U; Jacobs I
    BJOG; 2020 Feb; 127(3):364-375. PubMed ID: 31507061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population-based
    Tiller JM; Cousens NE; Kaur R; Rowley S; Ko YA; Mahale S; Bankier A; Meiser B; Barlow-Stewart K; Burnett L; Jacobs C; James P; Trainer A; Neil S; Campbell IG; Andrews L; Delatycki M
    J Med Genet; 2023 Mar; 60(3):265-273. PubMed ID: 36763037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term secondary lifestyle behavioural outcomes.
    Burnell M; Gaba F; Sobocan M; Desai R; Sanderson S; Loggenberg K; Gessler S; Side L; Brady AF; Dorkins H; Wallis Y; Jacobs C; Legood R; Beller U; Tomlinson I; Wardle J; Menon U; Jacobs I; Manchanda R
    BJOG; 2022 Nov; 129(12):1970-1980. PubMed ID: 35781768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective Cohort Study on the Limitations of Direct-to-Consumer Genetic Screening in Hereditary Breast and Ovarian Cancer.
    Desai NV; Barrows ED; Nielsen SM; Hatchell KE; Anderson MJ; Haverfield EV; Herrera B; Esplin ED; Lucassen A; Tung NM; Isaacs C
    JCO Precis Oncol; 2023 Aug; 7():e2200695. PubMed ID: 37535880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a Carrier Screening Program in a High-Risk Undergraduate Student Population Using Digital Marketing, Online Education, and Telehealth.
    Hardy MW; Kener HJ; Grinzaid KA
    Public Health Genomics; 2018; 21(1-2):67-76. PubMed ID: 30408784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of two population screening programmes for
    Cousens NE; Tiller J; Meiser B; Barlow-Stewart K; Rowley S; Ko YA; Mahale S; Campbell IG; Kaur R; Bankier A; Burnett L; Jacobs C; James PA; Trainer A; Neil S; Delatycki MB; Andrews L
    BMJ Open; 2021 Jun; 11(6):e041186. PubMed ID: 34172541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations.
    Lacour RA; Westin SN; Meyer LA; Wingo SN; Schorge JO; Brooks R; Mutch D; Molina A; Sutphen R; Barnes M; Elder J; Teoh D; Powell CB; Choubey V; Blank S; Macdonald HR; Brady MF; Urbauer DL; Bodurka D; Gershenson DM; Lu KH
    Gynecol Oncol; 2011 May; 121(2):358-63. PubMed ID: 21276604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry.
    Manchanda R; Patel S; Antoniou AC; Levy-Lahad E; Turnbull C; Evans DG; Hopper JL; Macinnis RJ; Menon U; Jacobs I; Legood R
    Am J Obstet Gynecol; 2017 Nov; 217(5):578.e1-578.e12. PubMed ID: 28690137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial.
    Manchanda R; Loggenberg K; Sanderson S; Burnell M; Wardle J; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; McGuire A; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):379. PubMed ID: 25435541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Jewish cultural and religious factors and uptake of population-based BRCA testing across denominations: a cohort study.
    Reisel D; Burnell M; Side L; Loggenberg K; Gessler S; Desai R; Sanderson S; Brady AF; Dorkins H; Wallis Y; Jacobs C; Legood R; Beller U; Tomlinson I; Wardle J; Menon U; Jacobs I; Manchanda R
    BJOG; 2022 May; 129(6):959-968. PubMed ID: 34758513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes and interest in incorporating BRCA1/2 cancer susceptibility testing into reproductive carrier screening for Ashkenazi Jewish men and women.
    Hardy MW; Peshkin BN; Rose E; Ladd MK; Binion S; Tynan M; McBride CM; Grinzaid KA; Schwartz MD
    J Community Genet; 2022 Jun; 13(3):281-292. PubMed ID: 35486291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA genetic testing of individuals from families with low prevalence of cancer: experiences of carriers and implications for population screening.
    Shkedi-Rafid S; Gabai-Kapara E; Grinshpun-Cohen J; Levy-Lahad E
    Genet Med; 2012 Jul; 14(7):688-94. PubMed ID: 22481128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women.
    Patel S; Legood R; Evans DG; Turnbull C; Antoniou AC; Menon U; Jacobs I; Manchanda R
    Am J Obstet Gynecol; 2018 Apr; 218(4):431.e1-431.e12. PubMed ID: 29288066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.
    Manchanda R; Legood R; Burnell M; McGuire A; Raikou M; Loggenberg K; Wardle J; Sanderson S; Gessler S; Side L; Balogun N; Desai R; Kumar A; Dorkins H; Wallis Y; Chapman C; Taylor R; Jacobs C; Tomlinson I; Beller U; Menon U; Jacobs I
    J Natl Cancer Inst; 2015 Jan; 107(1):380. PubMed ID: 25435542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experiences from a pilot program bringing BRCA1/2 genetic screening to theUS Ashkenazi Jewish population.
    Wiesman C; Rose E; Grant A; Zimilover A; Klugman S; Schreiber-Agus N
    Genet Med; 2017 May; 19(5):529-536. PubMed ID: 27735926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population screening for BRCA1/BRCA2 founder mutations in Ashkenazi Jews: proactive recruitment compared with self-referral.
    Lieberman S; Tomer A; Ben-Chetrit A; Olsha O; Strano S; Beeri R; Koka S; Fridman H; Djemal K; Glick I; Zalut T; Segev S; Sklair M; Kaufman B; Lahad A; Raz A; Levy-Lahad E
    Genet Med; 2017 Jul; 19(7):754-762. PubMed ID: 27929526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identifying Ashkenazi Jewish BRCA1/2 founder variants in individuals who do not self-report Jewish ancestry.
    Tennen RI; Laskey SB; Koelsch BL; McIntyre MH; Tung JY
    Sci Rep; 2020 May; 10(1):7669. PubMed ID: 32376921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.